Sugi Predict

Sugi Predict / Compounds / SCHEMBL10072161

SCHEMBL10072161

SCHEMBL10072161

Ic1c[nH]c2nccnc12

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 5/20 0.56
▸ CHEK1 O14757 1/20 0.39
▸ AXL P30530 1/20 0.32
▸ MAPK14 Q16539 1/20 0.32
▸ GPR84 Q9NQS5 1/20 0.31
▸ DYRK1A Q13627 1/20 0.31
▸ CCNB2 O95067 2/20 0.31
▸ CDK1 P06493 2/20 0.31
▸ CCNB1 P14635 2/20 0.31
▸ GSK3A P49840 2/20 0.31
▸ GSK3B P49841 2/20 0.31
▸ CDK5 Q00535 2/20 0.31
▸ CDK5R1 Q15078 2/20 0.31
▸ CCNB3 Q8WWL7 2/20 0.31
▸ PIM1 P11309 1/20 0.31
▸ HASPIN Q8TF76 1/20 0.31
▸ MAP2K1 Q02750 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30491471 0.83 MAPK1 (0.46) MAPK1CHEK1
SCHEMBL4878480 0.71 MAPK1 (0.56) MAPK1AXLGPR84DYRK1ACCNB2
SCHEMBL20118242 0.71 MAPK1 (0.56) MAPK1AXLGPR84CCNB2CDK1
SCHEMBL545193 0.71 MAPK1 (1.00) MAPK1AXLGPR84PIM1HASPIN
SCHEMBL31150717 0.71 MAPK1 (0.56) MAPK1CHEK1AXLGPR84DYRK1A
SCHEMBL30828747 0.71 MAPK1 (0.56) MAPK1AXLMAPK14GPR84GSK3B
SCHEMBL12657766 0.71 MAPK1 (0.67) MAPK1CHEK1
SCHEMBL21820855 0.69 MAPK1 (0.49) MAPK1CHEK1CCNB2CDK1CCNB1
SCHEMBL21821096 0.69 MAPK1 (0.62) MAPK1CHEK1
SCHEMBL31229864 0.69 MAPK1 (0.49) MAPK1CHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3555095-B1 INHIBITORS OF INFLUENZA VIRUS REPLICATION AND USES THEREOF SUNSHINE LAKE PHARMA CO LTD (CN) 2023-04-12 — — EP disclosed
US-10987354-B2 Inhibitors of influenza virus replication and uses thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2021-04-27 — — US disclosed
WO-2021032148-A1 AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF BEIGENE, LTD. (KY) 2021-02-25 — — WO disclosed
CN-108218873-B Inhibitors of influenza virus replication and uses thereof 广东东阳光药业有限公司 2020-07-07 — — CN disclosed
US-20200085822-A1 INHIBITORS OF INFLUENZA VIRUS REPLICATION AND USES THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2020-03-19 — — US disclosed
US-9873693-B2 Methods of treatment using pyridinonyl PDK1 inhibitors SUNESIS PHARMACEUTICALS, INC. (US) 2018-01-23 — — US disclosed
US-9873693-B2 Methods of treatment using pyridinonyl PDK1 inhibitors SUNESIS PHARMACEUTICALS, INC. (US) 2018-01-23 — — US disclosed
US-9382257-B2 Substituted pyrrolo[2,3-b]pyrazines as serine/threonine kinase inhibitors GENENTECH, INC. (US) 2016-07-05 — — US disclosed
CN-103168042-B 7-([1,2,3]-triazole-4-yl) pyrrolo-[2,3-b] pyrazines derivatives MERCK PATENT GMBH (DE) 2015-10-21 — — CN disclosed
EP-2909206-A1 SERINE/THREONINE KINASE INHIBITORS F. Hoffmann-La Roche AG (CH) 2015-08-26 — — EP disclosed
US-8865715-B2 Substituted 7-(1,2,3-Triazol-4-yl)-pyrrolo[2,3-b]pyrazines MERCK PATENT GMBH (DE) 2014-10-21 — — US disclosed
US-8778977-B2 Pyridinonyl PDK1 inhibitors SUNESIS PHARMACEUTICALS, INC. (US) 2014-07-15 — — US disclosed
US-8778977-B2 Pyridinonyl PDK1 inhibitors SUNESIS PHARMACEUTICALS, INC. (US) 2014-07-15 — — US disclosed
WO-2014060395-A1 SERINE/THREONINE KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2014-04-24 — — WO disclosed
US-20130217951-A1 7-(1,2,3-TRIAZOL-4-YL) PYRROLO [2,3-B] PYRAZINE DERIVATIVES MERCK PATENT GMBH (DE) 2013-08-22 — — US disclosed
US-20130217951-A1 7-(1,2,3-TRIAZOL-4-YL) PYRROLO [2,3-B] PYRAZINE DERIVATIVES MERCK PATENT GMBH (DE) 2013-08-22 — — US disclosed
US-20130217951-A1 7-(1,2,3-TRIAZOL-4-YL) PYRROLO [2,3-B] PYRAZINE DERIVATIVES MERCK PATENT GMBH (DE) 2013-08-22 — — US disclosed
WO-2012059171-A1 7-([1,2,3]TRIAZOL-4-YL)-PYRROLO[2,3-B]PYRAZINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-05-10 — — WO disclosed
US-20100144730-A1 PYRIDINONYL PDK1 INHIBITORS SUNESIS PHAMACEUTICALS (US) 2010-06-10 — — US disclosed
US-20100144730-A1 PYRIDINONYL PDK1 INHIBITORS SUNESIS PHAMACEUTICALS (US) 2010-06-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10987354-B2 Inhibitors of influenza virus replication and uses thereof ZC3HAV1, MAVS, POLRMT MAPK1 2020/4885CHEK1 1527/4885AXL 1707/4885
US-20100144730-A1 PYRIDINONYL PDK1 INHIBITORS PDK1, PDK2, PDK3 MAPK1 530/4885CHEK1 186/4885AXL 3196/4885
US-20130217951-A1 7-(1,2,3-TRIAZOL-4-YL) PYRROLO [2,3-B] PYRAZINE DERIVATIVES PDK1, PDK2, PDK3 MAPK1 182/4885CHEK1 144/4885AXL 2034/4885
US-20200085822-A1 INHIBITORS OF INFLUENZA VIRUS REPLICATION AND USES THEREOF ZC3HAV1, MAVS, POLRMT MAPK1 2020/4885CHEK1 1527/4885AXL 1707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.